{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=control+2&page=38",
    "query": {
      "intervention": "control 2",
      "page": 38
    },
    "page_size": 10
  },
  "pagination": {
    "page": 38,
    "page_size": 10,
    "total_count": 22182,
    "total_pages": 2219,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=control+2&page=39&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=control+2&page=37&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-28T22:30:59.544Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT06887673",
      "title": "Lipid Mediators & Cancer: Montelukast, SPM, and Almonds",
      "overall_status": "NOT_YET_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "EARLY_PHASE1"
      ],
      "conditions": [
        "Colorectal Cancer",
        "Sarcoma",
        "Brain Tumors",
        "Endometrial Cancer",
        "Ovarian Cancer"
      ],
      "interventions": [
        {
          "name": "No Interventions",
          "type": "OTHER"
        },
        {
          "name": "Sports Pro Resolve 4 g",
          "type": "DIETARY_SUPPLEMENT"
        },
        {
          "name": "Double Wood SPM 4 g",
          "type": "DIETARY_SUPPLEMENT"
        },
        {
          "name": "20 California Sweet Almonds",
          "type": "DIETARY_SUPPLEMENT"
        },
        {
          "name": "Montelukast 10 Mg Oral Tablet",
          "type": "DRUG"
        },
        {
          "name": "Montelukast 10 Mg Oral Tablet and SPM 4 g",
          "type": "COMBINATION_PRODUCT"
        },
        {
          "name": "Cold- Pressed Almond Oil 30 mL",
          "type": "DIETARY_SUPPLEMENT"
        }
      ],
      "intervention_types": [
        "OTHER",
        "DIETARY_SUPPLEMENT",
        "DRUG",
        "COMBINATION_PRODUCT"
      ],
      "sponsor": "University of South Florida",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 56,
      "start_date": "2025-03",
      "completion_date": "2026-03",
      "has_results": false,
      "last_update_posted_date": "2025-03-20",
      "last_synced_at": "2026-10-28T22:30:59.544Z",
      "location_count": 2,
      "location_summary": "Tampa, Florida",
      "locations": [
        {
          "city": "Tampa",
          "state": "Florida"
        },
        {
          "city": "Tampa",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06887673"
    },
    {
      "nct_id": "NCT01115322",
      "title": "A Study to Evaluate the Potential of Tazarotene Foam to Cause a Reaction When Applied to the Skin and Exposed to Light on Healthy Volunteers",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Acne Vulgaris"
      ],
      "interventions": [
        {
          "name": "Tazarotene Foam without irradiation",
          "type": "DRUG"
        },
        {
          "name": "Tazarotene Foam with UVA and UVB irradiation",
          "type": "DRUG"
        },
        {
          "name": "Tazarotene Foam with UVA, UVB, and visible light",
          "type": "DRUG"
        },
        {
          "name": "Vehicle Foam without irradiation",
          "type": "DRUG"
        },
        {
          "name": "Vehicle Foam with UVA and UVB irradiation",
          "type": "DRUG"
        },
        {
          "name": "Vehicle Foam with UVA and UVB and visible light irradiation",
          "type": "DRUG"
        },
        {
          "name": "No Treatment without irradiation",
          "type": "DRUG"
        },
        {
          "name": "No Treatment with UVA and UVB irradiation",
          "type": "DRUG"
        },
        {
          "name": "No Treatment with UVA and UVB and visible light irradiation",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Stiefel, a GSK Company",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 38,
      "start_date": "2010-04-01",
      "completion_date": "2010-04-10",
      "has_results": false,
      "last_update_posted_date": "2017-06-20",
      "last_synced_at": "2026-10-28T22:30:59.544Z",
      "location_count": 1,
      "location_summary": "Scottsdale, Arizona",
      "locations": [
        {
          "city": "Scottsdale",
          "state": "Arizona"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01115322"
    },
    {
      "nct_id": "NCT01900522",
      "title": "Safety and Tolerability of Multiple Doses of ITI-214 in Healthy Adults and in Adults With Stable Schizophrenia",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Schizophrenia"
      ],
      "interventions": [
        {
          "name": "ITI-214 Dose A",
          "type": "DRUG"
        },
        {
          "name": "ITI-214 Dose B",
          "type": "DRUG"
        },
        {
          "name": "ITI-214 Dose C",
          "type": "DRUG"
        },
        {
          "name": "ITI-214 Dose D (Elderly)",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        },
        {
          "name": "ITI-214 Dose E",
          "type": "DRUG"
        },
        {
          "name": "ITI-214 Dose F",
          "type": "DRUG"
        },
        {
          "name": "ITI-214 Dose G",
          "type": "DRUG"
        },
        {
          "name": "ITI-214 Dose H",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Takeda",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 76,
      "start_date": "2013-07",
      "completion_date": "2014-12",
      "has_results": false,
      "last_update_posted_date": "2015-02-19",
      "last_synced_at": "2026-10-28T22:30:59.544Z",
      "location_count": 2,
      "location_summary": "Glendale, California • New York, New York",
      "locations": [
        {
          "city": "Glendale",
          "state": "California"
        },
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01900522"
    },
    {
      "nct_id": "NCT03420222",
      "title": "Study to Assess the Efficacy, Safety, and Tolerability of AVP-786 for the Treatment of Intermittent Explosive Disorder",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Intermittent Explosive Disorder"
      ],
      "interventions": [
        {
          "name": "AVP-786",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Otsuka Pharmaceutical Development & Commercialization, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 10,
      "start_date": "2018-01-18",
      "completion_date": "2018-12-28",
      "has_results": true,
      "last_update_posted_date": "2022-05-24",
      "last_synced_at": "2026-10-28T22:30:59.544Z",
      "location_count": 9,
      "location_summary": "Gainesville, Florida • Atlanta, Georgia • Chicago, Illinois + 6 more",
      "locations": [
        {
          "city": "Gainesville",
          "state": "Florida"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "New Bedford",
          "state": "Massachusetts"
        },
        {
          "city": "O'Fallon",
          "state": "Missouri"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03420222"
    },
    {
      "nct_id": "NCT05671653",
      "title": "A Study to Evaluate the Effect of the Experimental GLP-1 Drug PF-07081532 on Blood Levels of Common Birth Control Pills, and Drugs Omeprazole and Midazolam, and Effect of GLP-1 Drug Semaglutide on Midazolam Blood Levels in Healthy Adults With Weight in the Obesity Range",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Obesity"
      ],
      "interventions": [
        {
          "name": "PF-07081532",
          "type": "DRUG"
        },
        {
          "name": "Semaglutide",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Pfizer",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "18 Years and older · Female only"
      },
      "enrollment_count": 32,
      "start_date": "2023-01-19",
      "completion_date": "2023-11-03",
      "has_results": true,
      "last_update_posted_date": "2025-01-14",
      "last_synced_at": "2026-10-28T22:30:59.544Z",
      "location_count": 1,
      "location_summary": "Anaheim, California",
      "locations": [
        {
          "city": "Anaheim",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05671653"
    },
    {
      "nct_id": "NCT04758637",
      "title": "AESOPS Trial 2 (AESOPS-2): Availability of Opioid Harm",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Opioid Abuse"
      ],
      "interventions": [
        {
          "name": "Overdose Notification",
          "type": "BEHAVIORAL"
        }
      ],
      "intervention_types": [
        "BEHAVIORAL"
      ],
      "sponsor": "University of Southern California",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 61,
      "start_date": "2023-01-23",
      "completion_date": "2024-03-18",
      "has_results": true,
      "last_update_posted_date": "2025-10-07",
      "last_synced_at": "2026-10-28T22:30:59.544Z",
      "location_count": 1,
      "location_summary": "Chicago, Illinois",
      "locations": [
        {
          "city": "Chicago",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04758637"
    },
    {
      "nct_id": "NCT02916472",
      "title": "CyberCycling to Reduce Therapeutic Side Effects and Improve Quality of Life in AYA Cancers",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Adolescent and Young Adult Cancers"
      ],
      "interventions": [
        {
          "name": "CyberCycling",
          "type": "BEHAVIORAL"
        },
        {
          "name": "Stretching",
          "type": "BEHAVIORAL"
        },
        {
          "name": "Resistance Bands",
          "type": "BEHAVIORAL"
        }
      ],
      "intervention_types": [
        "BEHAVIORAL"
      ],
      "sponsor": "Case Comprehensive Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "15 Years",
        "maximum_age": "30 Years",
        "sex": "ALL",
        "summary": "15 Years to 30 Years"
      },
      "enrollment_count": 9,
      "start_date": "2016-08-24",
      "completion_date": "2024-02-23",
      "has_results": false,
      "last_update_posted_date": "2024-03-01",
      "last_synced_at": "2026-10-28T22:30:59.544Z",
      "location_count": 1,
      "location_summary": "Cleveland, Ohio",
      "locations": [
        {
          "city": "Cleveland",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02916472"
    },
    {
      "nct_id": "NCT07800195",
      "title": "Probiotic Milk Drink for Gut and Brain Health in Older Adults and Caregivers",
      "overall_status": "NOT_YET_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Alzheimer Disease Related Dementia"
      ],
      "interventions": [
        {
          "name": "Probiotic Fermented Milk (PFM) Drink",
          "type": "DIETARY_SUPPLEMENT"
        },
        {
          "name": "Placebo",
          "type": "DIETARY_SUPPLEMENT"
        }
      ],
      "intervention_types": [
        "DIETARY_SUPPLEMENT"
      ],
      "sponsor": "University of South Florida",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 40,
      "start_date": "2026-09-01",
      "completion_date": "2026-10-20",
      "has_results": false,
      "last_update_posted_date": "2026-09-02",
      "last_synced_at": "2026-10-28T22:30:59.544Z",
      "location_count": 1,
      "location_summary": "Tampa, Florida",
      "locations": [
        {
          "city": "Tampa",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07800195"
    },
    {
      "nct_id": "NCT07306754",
      "title": "A Phase 1 Study to Evaluate the Safety and Pharmacokinetics of ABBV-243 in Healthy Adults.",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Healthy Volunteers"
      ],
      "interventions": [
        {
          "name": "ABBV-243",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "AbbVie",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "60 Years",
        "sex": "ALL",
        "summary": "18 Years to 60 Years"
      },
      "enrollment_count": 66,
      "start_date": "2025-12-17",
      "completion_date": "2027-05",
      "has_results": false,
      "last_update_posted_date": "2026-01-12",
      "last_synced_at": "2026-10-28T22:30:59.544Z",
      "location_count": 1,
      "location_summary": "Grayslake, Illinois",
      "locations": [
        {
          "city": "Grayslake",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07306754"
    },
    {
      "nct_id": "NCT05061966",
      "title": "The Digital Wellbeing Project",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Mental Health"
      ],
      "interventions": [
        {
          "name": "immi",
          "type": "BEHAVIORAL"
        },
        {
          "name": "Control",
          "type": "BEHAVIORAL"
        }
      ],
      "intervention_types": [
        "BEHAVIORAL"
      ],
      "sponsor": "University of Pennsylvania",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "13 Years",
        "maximum_age": "19 Years",
        "sex": "ALL",
        "summary": "13 Years to 19 Years"
      },
      "enrollment_count": 270,
      "start_date": "2021-09-15",
      "completion_date": "2022-07-01",
      "has_results": true,
      "last_update_posted_date": "2023-06-05",
      "last_synced_at": "2026-10-28T22:30:59.544Z",
      "location_count": 1,
      "location_summary": "Philadelphia, Pennsylvania",
      "locations": [
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05061966"
    }
  ]
}